MedPath

Cysteine

Generic Name
Cysteine
Brand Names
Elcys, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Nouress, Premasol, Primene, Procalamine 3, Trophamine 10 %
Drug Type
Small Molecule
Chemical Formula
C3H7NO2S
CAS Number
52-90-4
Unique Ingredient Identifier
K848JZ4886
Background

A thiol-containing non-essential amino acid that is oxidized to form cystine.

Indication

For the prevention of liver damage and kidney damage associated with overdoses of acetaminophen

Associated Therapies
Total parenteral nutrition therapy, Amino acid supplementation
Clinical Trials
Related News

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

Phase 2
Active, not recruiting
Conditions
Neurofibromatosis 1
Interventions
Other: Placebo
First Posted Date
2020-07-22
Last Posted Date
2024-10-09
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
58
Registration Number
NCT04481048
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

The ACTS Trial: N-acetylcysteine (NAC) and Night-splinting as a Non-operative Treatment for Carpal Tunnel Syndrome

Phase 4
Recruiting
Conditions
Carpal Tunnel
Carpal Tunnel Release
Hand Injuries and Disorders
Splints
Carpal Tunnel Syndrome
Nerve Compression
Interventions
Device: Wrist Splint
First Posted Date
2020-07-07
Last Posted Date
2024-08-23
Lead Sponsor
Emily Krauss
Target Recruit Count
240
Registration Number
NCT04460521
Locations
🇨🇦

Queen Elizabeth II Health Sciences Center, Halifax Infirmary Site, Halifax, Nova Scotia, Canada

Inflammatory Regulation Effect of NAC on COVID-19 Treatment

Phase 3
Conditions
COVID-19
Interventions
Drug: Placebo
First Posted Date
2020-07-02
Last Posted Date
2020-07-21
Lead Sponsor
Dr. Tariq Alhawassi
Target Recruit Count
1180
Registration Number
NCT04455243

The Efficacy of N-acetylcysteine Versus Placebo for the Treatment of Metamphetamine Withdrawal Symptoms

Phase 2
Completed
Conditions
Methamphetamine Dependence in Remission
Interventions
Drug: Placebo
First Posted Date
2020-05-28
Last Posted Date
2021-02-10
Lead Sponsor
Melva Louisa
Target Recruit Count
66
Registration Number
NCT04405193
Locations
🇮🇩

Rehabilitation Center, National Narcotics Agency, Bogor, West Java, Indonesia

Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome

Phase 2
Not yet recruiting
Conditions
Cornelia de Lange Syndrome
Interventions
Other: Placebo
First Posted Date
2020-05-11
Last Posted Date
2025-04-02
Lead Sponsor
Johns Hopkins University
Target Recruit Count
10
Registration Number
NCT04381897
Locations
🇺🇸

Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial

Phase 3
Active, not recruiting
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: Placebo
First Posted Date
2020-03-09
Last Posted Date
2024-12-24
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
202
Registration Number
NCT04300920
Locations
🇺🇸

Piedmont Healthcare, Austell, Georgia, United States

🇺🇸

Loyola University, Maywood, Illinois, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

and more 22 locations

Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.

Phase 1
Recruiting
Conditions
Ototoxic Hearing Loss
Interventions
First Posted Date
2020-03-02
Last Posted Date
2023-09-06
Lead Sponsor
Sunnybrook Health Sciences Centre
Target Recruit Count
80
Registration Number
NCT04291209
Locations
🇨🇦

Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Prospective Analysis of the Use of N-Acetylcysteine and Vitamins in the Treatment of TBI in Geriatric Patients

Phase 2
Completed
Conditions
Traumatic Brain Injury
Interventions
First Posted Date
2020-03-02
Last Posted Date
2021-09-01
Lead Sponsor
HonorHealth Research Institute
Target Recruit Count
92
Registration Number
NCT04291066
Locations
🇺🇸

HonorHealth Deer Valley Medical Center, Phoenix, Arizona, United States

🇺🇸

HonorHealth John C. Lincoln Medical Center, Phoenix, Arizona, United States

The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major

Phase 1
Completed
Conditions
Thalassemia Major
Interventions
First Posted Date
2020-02-07
Last Posted Date
2020-02-07
Lead Sponsor
Beni-Suef University
Target Recruit Count
100
Registration Number
NCT04260516
Locations
🇪🇬

Heba Mostafa Ahmed, Banī Suwayf, Beni Suef, Egypt

Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity

Phase 4
Terminated
Conditions
Ototoxic Hearing Loss
Ototoxic Hearing Loss, Bilateral
Ototoxicity
Tinnitus
Interventions
First Posted Date
2020-01-13
Last Posted Date
2023-10-24
Lead Sponsor
Centre Hospitalier Universitaire Saint Pierre
Target Recruit Count
19
Registration Number
NCT04226456
Locations
🇧🇪

CHU Saint-Pierre, Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy